• Explore /
  • Poster
  • / The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.

The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.

Abstract Poster

Authors

null

J. A. Thompson

Seattle Cancer Care Alliance, Seattle, WA

J. A. Thompson , A. Forero-Torres , E. I. Heath , S. M. Ansell , S. K. Pal , J. R. Infante , S. De Vos , P. A. Hamlin , B. Zhao , K. Klussman , N. C. Whiting

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Other Novel Agents

Clinical Trial Registration Number

NCT01015911

Citation

J Clin Oncol 29: 2011 (suppl; abstr 3071)

Abstract #

3071

Poster Bd #

15D

Abstract Disclosures

Similar Posters

First Author: Victor Moreno

First Author: John C. Byrd

First Author: Jianxiang Wang

First Author: Don A. Stevens